Wall Street research analysts offer views on future stock movement of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). These opinions are based on extensive research and broad knowledge of the company. Analysts polled by Thomson Reuters have set a consensus target price of $18.00 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets.
Wall Street analysts have the ability to use various metrics to help calculate target projections. A commonly used metric is a company’s P/E Ratio. This calculation stems from dividing the current share price by the projected earnings per share. At the time of this writing, Oramed Pharmaceuticals Inc. has a price to earnings ratio of N/A. Investors may also evaluate a company’s PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may indicate that the company is overvalued. A PEG Ratio near one may be seen as fair value. The stock presently has a PEG Ratio of 0.00.
Taking a brief view of stock performance, we see that company shares are currently trading $0.14 off the 50-day moving average of $6.34 and $-0.35 off of the 200-day moving average of $6.83. The stock has been recently recorded -38.34% off of the 52-week high of 10.51 and +13.68% away from the 52-week low of 5.70. Tracking the stock price relative to moving averages and highs and lows for the year may help evaluate the future value of the stock.